Chichi Huang

USPTO Granted Patents = 22 (Patent Applications = 11)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 5)

Average Co-Inventor Count = 5.6

ph-index = 5

Forward Citations = 109(Granted Patents)

Location History:

Radnor, PA (US) (2011 - 2014)
Berwyn, PA (US) (2008 - 2021)
Spring House, PA (US) (2018 - 2023)
Malvern, PA (US) (2019 - 2023)

Company Filing History:

12 out of 410

Janssen Biotech, Inc.

patents

3 out of 60

Janssen Sciences Ireland Unlimited Company

Centocor Ortho Biotech Inc.

Janssen Pharmaceutica Nv

patents

7. 1 out of 832,680

Other

patents

Years Active: 2008-2025

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12275770 - Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof (2025-04-14),

2. 12269870 - Antigen binding regions against fibronectin type III domains and methods of using the same (2025-04-08),

3. 11787875 - Materials and methods for improved single chain variable fragments (2023-10-17),

4. 11713345 - Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof (2023-08-01),

5. 11603405 - Anti-CD3 antibodies and uses thereof (2023-03-14),

6. 11236155 - Antibodies to pyroglutamate amyloid-β and uses thereof (2022-02-01),

7. 11208464 - GDF15 fusion proteins and uses thereof (2021-12-28),

8. 11161897 - Antigen binding regions against fibronectin type III domains and methods of using the same (2021-11-02),

9. 10759854 - Interferon alpha and omega antibody antagonists (2020-09-01),

10. 10358491 - Interferon alpha and omega antibody antagonists (2019-07-23),

11. 10336812 - GDF15 fusion proteins and uses thereof (2019-07-02),

12. 10208113 - Interferon α and ω antibody antagonists (2019-02-19),

13. 10179808 - Kv1.3 antagonists and methods of use (2019-01-15),

14. 10155809 - Interferon alpha and omega antibody antagonists (2018-12-18),

15. 9902770 - Interferon alpha and omega antibody antagonists (2018-02-27),

Title: Chichi Huang: A Leader in Pharmaceutical Innovations

Introduction

Chichi Huang, based in Berwyn, PA, is a prominent inventor known for his significant contributions to the field of biotechnology and pharmaceuticals. With a remarkable portfolio of 20 patents, Huang has demonstrated an unwavering commitment to advancing medical technology and therapeutic solutions.

Latest Patents

Among his latest patents are cutting-edge innovations such as "Materials and methods for improved single chain variable fragments," which outlines new methodologies for enhancing the efficacy of single chain variable fragments. Another notable patent is "Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof," which details the development of fusion proteins comprising GLP1 or its variants, linker peptides, serum albumin, and GDF15 protein, offering novel therapeutic possibilities.

Career Highlights

Huang's career has seen him collaborate with leading companies in the pharmaceutical industry, including Janssen Biotech, Inc. and Centocor, Inc. His expertise in biomedical innovations has positioned him at the forefront of research and development, making substantial impacts on patient care and treatment options.

Collaborations

Throughout his career, Chichi Huang has had the privilege of working alongside esteemed colleagues such as Xiefan Lin-Schmidt and Judith Ann Connor. These collaborations have fostered a rich environment for innovation, allowing for the exchange of ideas and the advancement of groundbreaking technologies.

Conclusion

Chichi Huang's impressive track record of patents and collaborations underscores his role as a driving force in the world of pharmaceutical innovation. His work continues to influence the healthcare industry, paving the way for future advancements in medical treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.